Hemoglobinopathies Market Overview
Hemoglobinopathies is another term for hemoglobinopathy. It is a medical term for a collection of blood illnesses and diseases affecting red blood cells. Hemoglobinopathies are single-gene illnesses that are inherited as autosomal co-dominant features in the majority of instances.
Because of the increased prevalence of hemoglobin diseases such as sickle cell anaemia, thalassemia, Hb C, and Hb E, the global hemoglobinopathies market overview is expected to fuel market expansion. In low-income locations such as South-East Asia, the Mediterranean basin, and Africa, poor hygiene and healthcare facilities are also major contributors to the target population's growth.
Hemoglobinopathies Market Segmentation
The global hemoglobinopathies market is segmented based on type, treatment, test types, and region.
The global market for hemoglobinopathies, by type, is segmented into thalassemia, sickle cell disease, and other Hb variants diseases. The thalassemia segment is further classified as alpha thalassemia and beta thalassemia. The sickle cell disease segment is expected to hold the largest market share of the hemoglobinopathies market owing to the presence of strong product pipelines such as LentiGlobin and rising prevalence of sickle cell disease.
- Based on treatment, the market is classified into stem-cell transplantation, blood transfusions, analgesics, antibiotics, ACE inhibitors, and hydroxyurea. Also, based on treatment, the blood transfusion segment holds the largest market share owing to significant success rate and increasing adoption of this treatment option.
- The market by end user, has been segmented into hospitals clinics, diagnostics laboratories, hemoglobin analyzer and others.
- On the basis of region, the global hemoglobinopathies market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
Hemoglobinopathies Market Regional Analysis
The global hemoglobinopathies market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East Africa. The hemoglobinopathies market in the Americas has further been segmented into North America and South America, with the North America market further classified into the US and Canada.
The European hemoglobinopathies market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The hemoglobinopathies market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific.
The hemoglobinopathies market in the Middle East Africa has been segmented into the Middle East and Africa.
Hemoglobinopathies Market Players:
Some of the key players in the global hemoglobinopathies market are Sanofi, Sangamo Therapeutics Inc., Global Blood Therapeutics, Bluebird Bio Inc., Emmaus Life Sciences Inc., Prolong Pharmaceuticals, Celgene Corporation, Alnylam Pharmaceuticals, Gamida Cell, Acceleron Pharma, Mast Therapeutic, HemaQuest Pharmaceuticals, and Invenux.
among others are some key companies in the global hemoglobinopathies that are listed by MRFR for market research.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: info@marketresearchfuture.com
